DIZAL JIANGSU
PharmaDIZAL JIANGSU is a pharmaceutical company focused on Oncology. Key products include ZEGFROVY.
FDA Novel Drug Designations
(2025)See 1 novel approval →
DIZAL JIANGSU's Key Drugs
DIZAL JIANGSU's core commercial portfolio centers on ZEGFROVY, spanning Oncology — its most strategically important drugs approved in the last 15 years.
DIZAL JIANGSU's Recent FDA Approvals
DIZAL JIANGSU secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
DIZAL JIANGSU's Therapeutic Areas
DIZAL JIANGSU's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DIZAL JIANGSU's Top Competitors
DIZAL JIANGSU's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DIZAL JIANGSU Pipeline Snapshot
DIZAL JIANGSU has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZEGFROVY leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/2 completed
- • Speed: N/A months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-07-02
- Latest
- 2025-07-02
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges